Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-10-28
1996-07-30
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514313, 514314, 514338, 514463, 546173, 546174, 5462837, 549298, 549358, 549432, A61K 3136, A61K 31365, C07D30777
Patent
active
055412238
ABSTRACT:
Novel podophyllotoxin compounds and their use in treating tumors are disclosed. The analogs have the general formula: ##STR1## wherein NH--R is a selected aryl amine, dialkylaminoalkyleneamino, or dialkylaminoanilino group.
REFERENCES:
patent: 5132322 (1992-07-01), Lee et al.
Ayres, D. C., and Lim, C. K., "Modification of the Pendant Ring of Podophyllotoxin," Cancer Chemother. Pharmacol. 7:99-101.
Chen, G. L., et al., "Nonintercalative Antitumor Drugs Interfere with the Breakage-Reunion Reaction of Mammalian DNA Topoisomerase II," J. Biol. Chem. 259(21):13560-13566 (1987).
Lee, K. H., et al., "Antitumor Agents, 107, New Cytotoxic 4-Alkylamino Analogues of 4'-Demethyl-epipodophyllotoxin as Inhibitors of Human DNA Topoisomerase II," J. Natur. Prod. 52(3):606-613 (1989).
Liu, L. F., et al., "Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases," Nuc. Acids Res. 9(16):3979-3989 (1981).
Maxwell, A., and Gellert, M., "Mechanistic Aspects of DNA Topoisomerases," Adv. Protein Chem. 38:69-107 (1986).
Minocha, A., and Long, B. H., "Inhibition of the DNA Catenation Activity of Type II Topoisomerase by VP16-213 and VM26," Biochem. Biophys. Res. Comm. 122(1):165-170 (1984).
Ross, W., et al., "Role of Topoisomerase II in Mediating Epipodophyllotoxin-induced DNA Cleavage," Cancer Res. 44:5857-5860 (1984).
Rowe, T. C., et al., "DNA Damage by Antitumor Acridines Mediated by Mammalian DNA Topoisomerase II," Cancer Res. 46:2021-2026 (1986).
Rowe, T., et al., "Inhibition of Epipodophyllotoxin Cytotoxicity by Interference with Topoisomerase-Mediated DNA Cleavage," Biochem. Pharmacol. 34(14):2483-2487 (1985).
Thurston, L. S., et al., "Antitumor Agents. 78. Inhibition of Human DNA Topoisomerase II by Podophyllotoxin and .alpha.-Peltatin Analogues," J. Med. Chem. 29:1547-1550 (1986).
Thurston, L. S., et al., "Antitumor Agents. 100. Inhibition of Human DNA Topoisomerase II by Cytotoxic Ether and Ester Derivatives of Podophyllotoxin and .alpha.-Peltatin," J. Med. Chem. 32:604-608 (1989).
Wang, J. C., "DNA Topoisomerases," Ann. Rev. Biochem. 54:665-697 (1985).
Lee et al, "J. Med. Chem., " 33(5), pp. 1364-1368, 1990.
Wang et al, "J. Med. Chem.,", 33(9), pp. 2660-2666, 1990.
Chang et al, "Cancer Research", 51, pp. 1755-1759, 1991.
Cheng Yung-Chi
Lee Kuo-Hsiung
Dehlinger Peter J.
Ivy C. Warren
Powers Vincent M.
The University of North Carolina at Chapel Hill
Trinh Ba K.
LandOfFree
4.beta.-amino podophyllotoxin analog compounds and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4.beta.-amino podophyllotoxin analog compounds and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4.beta.-amino podophyllotoxin analog compounds and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1659061